title: Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors.
abstract: There is overwhelming evidence that tyrosine kinases play an important role in cancer development. As a prototype of targeted therapy, tyrosine kinase inhibitors are now successfully applied to cancer treatment. However, as single agents, tyrosine kinase inhibitors have not achieved satisfactory results in the treatment of prostate cancer, principally due to their inability to efficiently kill tumor cells. The authors' laboratory has been interested in the role of the Src complex in prostate cancer progression, including the induction of androgen independence and metastasis. Previously, the authors reported that Src inhibitors such as saracatinib and PP2 caused G1 growth arrest and diminished invasiveness in prostate cancer cells but rarely apoptosis. Here, they have shown that Src family kinase (SFK) inhibitors can induce a high level of autophagy, which protects treated cells from undergoing apoptosis. Src siRNA knockdown experiments confirmed that autophagy was indeed caused by the lack of Src activity. The SFK inhibitor-induced autophagy is accompanied by the inhibition of the PI3K (type I)/Akt/mTOR signaling pathway. To test whether autophagy blockade could lead to enhanced cell death, pharmacological inhibitors (3-methyladenine and chloroquine) and a genetic inhibitor (siRNA targeting Atg7) were used in combination with SFK inhibitors. The results showed that autophagy inhibition effectively enhanced cell killing induced by SFK inhibitors. Importantly, the authors showed that a combination of saracatinib with chloroquine in mice significantly reduced prostate cancer (PC3) xenograft growth compared with the control group. Taken together, these data suggest that (1) autophagy serves a protective role in SFK inhibitor-mediated cell killing, and (2) clinically acceptable autophagy modulators may be used beneficially as adjunctive therapeutic agents for SFK inhibitors.
authors.affiliation: Department of Biological Chemistry and Molecular Medicine.
authors.forename: Zhaoju
authors.initials: Z
authors.lastname: Wu
authors.forename: Pei-Ching
authors.initials: PC
authors.lastname: Chang
authors.forename: Joy C
authors.initials: JC
authors.lastname: Yang
authors.forename: Cheng-Ying
authors.initials: CY
authors.lastname: Chu
authors.forename: Ling-Yu
authors.initials: LY
authors.lastname: Wang
authors.forename: Nien-Tsu
authors.initials: NT
authors.lastname: Chen
authors.forename: Ai-Hong
authors.initials: AH
authors.lastname: Ma
authors.forename: Sonal J
authors.initials: SJ
authors.lastname: Desai
authors.forename: Su Hao
authors.initials: SH
authors.lastname: Lo
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Evans
authors.forename: Kit S
authors.initials: KS
authors.lastname: Lam
authors.forename: Hsing-Jien
authors.initials: HJ
authors.lastname: Kung
references.citation: Leukemia. 2007 May;21(5):926-35
references.pmid: 17330101
references.citation: Anticancer Res. 2007 Mar-Apr;27(2):1095-104
references.pmid: 17465249
references.citation: Mol Cell Biol. 2001 Dec;21(24):8385-97
references.pmid: 11713275
references.citation: Blood. 2006 Jun 1;107(11):4532-9
references.pmid: 16469872
references.citation: J Biol Chem. 1995 Feb 3;270(5):2320-6
references.pmid: 7836465
references.citation: Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3644-9
references.pmid: 9520419
references.citation: Nature. 2008 Feb 28;451(7182):1069-75
references.pmid: 18305538
references.citation: Nat Rev Mol Cell Biol. 2007 Sep;8(9):741-52
references.pmid: 17717517
references.citation: Urol Oncol. 2009 Jan-Feb;27(1):48-52
references.pmid: 19111798
references.citation: Crit Rev Clin Lab Sci. 2009;46(4):210-40
references.pmid: 19552522
references.citation: Nat Rev Cancer. 2004 Jun;4(6):470-80
references.pmid: 15170449
references.citation: Oncogene. 2004 Mar 18;23(12):2197-205
references.pmid: 14767470
references.citation: J Clin Invest. 2008 Jan;118(1):79-88
references.pmid: 18097482
references.citation: Mol Cell Biol. 1994 Mar;14(3):1680-8
references.pmid: 7509446
references.citation: Oncogene. 2004 Apr 12;23(16):2891-906
references.pmid: 15077152
references.citation: Oncogene. 2008 Oct 23;27(49):6365-75
references.pmid: 18679417
references.citation: Curr Opin Pharmacol. 2008 Aug;8(4):427-32
references.pmid: 18625340
references.citation: BJU Int. 2009 Feb;103(4):434-40
references.pmid: 19154462
references.citation: Oncogene. 2007 Feb 1;26(5):745-56
references.pmid: 16862179
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Drugs. 2009 Nov 12;69(16):2303-28
references.pmid: 19852530
references.citation: Cancer Res. 2009 Jan 1;69(1):151-60
references.pmid: 19117998
references.citation: Neoplasia. 2007 Feb;9(2):90-100
references.pmid: 17357254
references.citation: Cell Death Differ. 2005 Nov;12 Suppl 2:1509-18
references.pmid: 16247498
references.citation: Nat Cell Biol. 2000 May;2(5):249-56
references.pmid: 10806474
references.citation: Cancer Res. 2006 Jun 1;66(11):5542-8
references.pmid: 16740687
references.citation: J Bone Miner Res. 2010 Mar;25(3):463-71
references.pmid: 19775203
references.citation: Cancer Res. 2006 Oct 15;66(20):10040-7
references.pmid: 17047067
references.citation: Cancer Res. 2009 Sep 15;69(18):7402-11
references.pmid: 19706771
references.citation: Cancer Res. 2005 Jun 15;65(12):5358-64
references.pmid: 15958584
references.citation: Clin Cancer Res. 2007 Dec 15;13(24):7232-6
references.pmid: 18094400
references.citation: Cancer Cell. 2004 Sep;6(3):209-14
references.pmid: 15380511
references.citation: Ann Oncol. 2008 Aug;19(8):1379-1386
references.pmid: 18487549
references.citation: Cancer Cell. 2006 Oct;10(4):309-19
references.pmid: 17045208
references.citation: Cancer Res. 2009 Jan 15;69(2):700-8
references.pmid: 19147587
references.citation: Autophagy. 2009 Nov;5(8):1131-44
references.pmid: 19786832
references.citation: BJU Int. 2009 Jan;103(2):171-7
references.pmid: 18990162
references.citation: Blood. 2007 Jul 1;110(1):313-22
references.pmid: 17363733
references.citation: J Cell Biol. 2005 Nov 21;171(4):603-14
references.pmid: 16286508
references.citation: Prostate Cancer Prostatic Dis. 2007;10(2):185-8
references.pmid: 17211440
references.citation: Clin Cancer Res. 2009 May 15;15(10):3540-9
references.pmid: 19447874
references.citation: J Clin Invest. 2009 May;119(5):1109-23
references.pmid: 19363292
references.citation: Proc Natl Acad Sci U S A. 1982 Mar;79(6):1889-92
references.pmid: 6952238
references.citation: Clin Ther. 2007 Nov;29(11):2289-308
references.pmid: 18158072
references.citation: J Cell Sci. 2004 Nov 1;117(Pt 23):5479-87
references.pmid: 15509864
references.citation: Curr Top Dev Biol. 2007;78:217-45
references.pmid: 17338918
references.citation: Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):10148-52
references.pmid: 7937853
references.citation: Mol Cancer Ther. 2009 Feb;8(2):394-406
references.pmid: 19190119
references.citation: EMBO J. 2000 Nov 1;19(21):5720-8
references.pmid: 11060023
references.citation: Cancer Res. 2005 Aug 15;65(16):7214-22
references.pmid: 16103072
references.citation: Mol Oncol. 2009 Aug;3(4):366-75
references.pmid: 19559660
references.citation: Anticancer Drugs. 2009 Mar;20(3):179-84
references.pmid: 19396016
references.citation: Cancer Res. 2008 Dec 1;68(23):9624-33
references.pmid: 19047139
references.citation: J Clin Invest. 2007 Feb;117(2):326-36
references.pmid: 17235397
references.citation: Mol Biol Cell. 1999 May;10(5):1367-79
references.pmid: 10233150
references.citation: Breast Cancer Res Treat. 2007 Nov;105(3):319-26
references.pmid: 17268817
references.citation: Nat Rev Cancer. 2007 Dec;7(12):961-7
references.pmid: 17972889
references.citation: Autophagy. 2007 Sep-Oct;3(5):464-7
references.pmid: 17495516
references.citation: Int J Biochem Cell Biol. 2004 Dec;36(12):2503-18
references.pmid: 15325588
references.citation: Nat Rev Clin Oncol. 2009 Oct;6(10):587-95
references.pmid: 19787002
references.citation: Cancer Res. 2008 May 1;68(9):3323-33
references.pmid: 18451159